Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194326 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10LMNAPMP22 | |
| SCHEMBL10327948 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10LMNAPMP22 | |
| SCHEMBL28647710 | 0.79 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10LMNAPMP22 | |
| SCHEMBL14358553 | 0.78 | CCNB2 (0.41) | KDM4EALDH1A1HSD17B10LMNAPMP22 | |
| SCHEMBL25272619 | 0.76 | TYRO3 (0.50) | KDM4EALDH1A1HSD17B10LMNAPMP22 | |
| SCHEMBL600816 | 0.74 | SIRT2 (0.42) | KDM4EALDH1A1HSD17B10LMNAPMP22 | |
| SCHEMBL587003 | 0.72 | KMT2A (0.45) | KDM4EHSD17B10LMNAPMP22SIRT2 | |
| SCHEMBL14901140 | 0.72 | MAPK1 (0.43) | PDE3BPDE3AHCAR1 | |
| SCHEMBL21855940 | 0.70 | MAPKAPK2 (0.42) | KDM4EALDH1A1HSD17B10LMNAMAPKAPK2 | |
| SCHEMBL31067714 | 0.70 | MAPKAPK2 (0.42) | KDM4EALDH1A1HSD17B10LMNAMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794939-A | Antibiotic pyrazinothiazine derivatives and process for their preparation | 巴格沃克斯研究印度私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112218862-B | Oxazolidinone antibiotic compounds and process for preparing same | 巴格沃克斯研究有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-3567041-B1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023017549-A1 | ANTIBIOTIC PYRAZINOTHIAZINE DERIVATIVES AND PROCESS OF PREPARATION THEREOF | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2023-02-16 | — | — | WO | disclosed |
| EP-3774790-B1 | OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113387962-A | Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013071264-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2575462-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | KDM4E 3602/4885ALDH1A1 3997/4885HSD17B10 4025/4885 |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 4173/4885ALDH1A1 2379/4885HSD17B10 1819/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | KDM4E 2754/4885ALDH1A1 4563/4885HSD17B10 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.